Recruiting

WHIMASWhite Matter Hyperintensity Shape and Glymphatics

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Mixed Dementias+16

+ Arterial Occlusive Diseases

+ Arteriosclerosis

Over 65 Years
See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: January 2023
See protocol details

Summary

Principal SponsorLeiden University Medical Center
Study ContactIngmar Eiling, MScMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: January 18, 2023

Actual date on which the first participant was enrolled.

Aim: The overall aim is to study how different pathological mechanisms in cerebral SVD influence WMH shape. Primary objective: To study the association of a more complex WMH shape with abnormalities in small vessel morphology. Secondary objectives: To study the association between WMH shape and cognition/other cerebral small vessel disease markers. To study the association of novel MRI markers of glymphatics with cerebral SVD markers and cognition. Study design: Cross-sectional study that will be conducted at the Leiden University Medical Center (LUMC). Patients will be included from the LUMC or the Alrijne Hospital Leiden. The study contains 3T and 7T MRI scans, as well as neuropsychological assessments. The data will be analyzed by performing association analysis. Study population: Patients of the memory/geriatric clinic that are over 65 years of age. Main study parameter/endpoint: In order to postulate underlying mechanisms related to WMH shape variations the investigators will study the association between a more complex WMH shape and structural and functional markers of cerebral SVD (such as lacunes and microbleeds). WMH shape is assessed as follows: Convexity, solidity, concavity index, and fractal dimension are calculated for periventricular/confluent WMH. A lower convexity and solidity, and higher concavity index and fractal dimension indicate a more irregular shape of periventricular/confluent WMH. For deep WMH, fractal dimension and eccentricity are determined. A higher eccentricity and fractal dimension indicate a more complex shape of deep WMH. Other study parameters: The investigators want to investigate WMH shape parameters and the association with cognition (mini-mental state exam, clinical dementia rating and cognitive domain scores). Another endpoint is to investigate if different WMH phenotypes can be identified (by machine learning models). Moreover, the association between SVD markers/cognition and novel glymphatics markers (such as size of perivascular spaces, CSF mobility and 4th ventricle CSF flow dynamics) will be investigated. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The participants will not directly benefit from the results of the study. However, their contribution to the study will add important information about the pathophysiology of the cerebrovascular pathology that contributes to dementia. Therefore, it is not possible to study the research question in a different population group. The ultra-high field 7T MRI system is widely used in a research setting and since its first introduction in the 1990s no serious adverse events have been reported. Important temporary side-effects are vertigo, nausea and involuntary eye motion due to forces on ion currents in the semicircular loops. As all MRI scans are performed within a maximum of 60 minutes and without any contrast agents, the participant burden is seen as a non-substantial burden.

Official TitleWhite Matter Hyperintensity Shape and Glymphatics
Principal SponsorLeiden University Medical Center
Study ContactIngmar Eiling, MScMore contacts
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Mixed DementiasArterial Occlusive DiseasesArteriosclerosisMental DisordersBrain DiseasesCardiovascular DiseasesCentral Nervous System DiseasesIntracranial ArteriosclerosisCerebrovascular DisordersCognition DisordersDementiaNervous System DiseasesVascular DiseasesDementia, VascularNeurocognitive DisordersIntracranial Arterial DiseasesLeukoencephalopathiesCerebral Small Vessel DiseasesCognitive Dysfunction

Criteria

Inclusion Criteria: * Admitted to the memory or the geriatric clinic of the LUMC, the Alrijne Hospital Leiden or the Haga Hospital the Hague * From 65 years of age * Eligible for MRI * Native-level Dutch speaker Exclusion Criteria: * Claustrophobia * Contraindications for MRI such as metal implants and pacemaker * Use of benzodiazepines * Initiated treatment with antidepressants less than 6 weeks prior to inclusion * Not being able to provide written informed consent (assessed by the treating physician) * Individuals that have been declared mentally incapacitated * Other severe neurological disease besides dementia related * Cognitive impairment due to known other neurological disease * Previous brain surgery

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Leiden University Medical Center

Leiden, NetherlandsOpen Leiden University Medical Center in Google Maps
Recruiting
One Study Center